Navigation Links
Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics
Date:11/6/2008

NOVATO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that data from clinical studies of Kuvan(R) (sapropterin dihydrochloride), Naglazyme(R) (galsulfase) and enzyme replacement therapies for MPS IVA (Morquio Syndrome) and Pompe disease will be presented at the 58th Annual Meeting of the American Society of Human Genetics (ASHG) in Philadelphia, Pennsylvania, November 11-15, 2008.

"We look forward to a number of poster presentations that will address a variety of investigator-sponsored trials now in progress. Results from these studies will add to our growing data set for Kuvan and Naglazyme and increase our understanding about the long term safety and efficacy of the drugs across different patient populations," said Chief Medical Officer Emil Kakkis, M.D., Ph.D.

The following posters will be featured:

590/W - "Implications of absence of clinical phenotype on Morquio A mice: Why rodents do not require skeleton keratan sulfate?"

752/W - "Intrathecal (IT) enzyme replacement therapy (ERT) for symptomatic spinal cord compression (SCC) in a MPS VI child: safety, efficacy, and pitfalls"

763/W - "Therapeutic response after two years of Galsulfase ERT in five adult patients with MPS VI"

2353/W - "MPS Brazil-Network: 4 years improving diagnosis and management of mucopolysaccharidoses in Brazil"

772/T - "PKU treatment with tetrahydrobiopterin (sapropterin) during pregnancy"

773/T - "A new strategy using sapropterin and placebo to determine the predictive value of mutation analysis towards identifying BH4 responsive hyperphenylalanemia"

774/T - "Interim results of a Phase II, multicenter, open-label study of sapropterin dihydrochlori
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
2. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
5. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
6. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
7. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
8. Salugens Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis
9. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
10. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
11. Promising Data ATIR Studies Presented by NIH Investigators

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... A mechanised blue dye test alter...ckaging quality assurance one step closer for phar... leak testing machine developed by Sepha for u...alled in several local and global pharma-companies...s quality assurance and productivity improvements ...
(Date:11/25/2009)...OSTON,Nov.25/PRNewswire/--BiotechfirmReplikinsLtd....18pandemicthroughtheprediction,outbreak,andprogres...hemicalanalysisofthevirus.Thenewdatashowsthatthele...peakof3.7(s.d.4.5)duringthevirus,scurrentoutbreaki...kof2.0(s.d.0.1).TheH1N1virus,infectivitycount,howe...
(Date:11/25/2009)...ARKHAM,ON,Nov.25/PRNewswire/-Cytochromatodayannoun...tors.Dr.MoldtwillreplaceMr.UlrikSporkastheNovoA/Sr...embersremainsunchangedatsixmembers. ,, "Weareve...rdtobenefitingfromhisexperienceandguidanceasCytoch...ocusedspecialtypharmaceuticalcompany,"statedAlanLe...
(Date:11/25/2009)...ANDIEGO,Nov.25/PRNewswire-FirstCall/--ArdeaBioscie...uart,Pharm.D.,presidentandchiefexecutiveofficer,wi...erence. , ,Presentationdetailsareasfollows:,Pipe...y,December1,2009,Time:2:00p.m.EasternTime,Location...http://www.corporate-ir.net/ireye/,target=,_blank...
Breaking Biology Technology:Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 2Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 3Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Cytochroma Announces Appointment of Peter Moldt to Board of Directors 2Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2
...igma-Aldrich Corporation,(Nasdaq: SIAL ), will ho...,quarter results on Wednesday, July 23, 2008, at 1...his call is being webcast by Thomson/CCBN and can .../www.sigma-aldrich.com ., The webcast is also be...etwork to both institutional and individual invest...
... Following First-in-Man study success, Ovalum...™ technology in the coronary arteries. Ovalu...mpany, has announced today successful experiences ...aversing chronic total occlusions in the coronary ...ael (PRWEB) July 11, 2008 -- Following First-in-Ma...
...ewswire-FirstCall/ - ARIUS Research Inc., (TSX:,AR...ping the next wave of,antibody therapeutics, today...or the second fiscal quarter of 2008, ended May 31...ntained our focus on moving,ARIUS, anti-cancer ant...,our lead drug candidates received significant att...
Other Biology Technology:Sigma-Aldrich Corporation's 2nd Quarter 2008 Earnings Conference Call 2Ovalum Ltd. Announces Success in Coronary Cases Using CiTop™ ExPander™ Guidewire 2ARIUS announces second quarter fiscal 2008 financial results 2ARIUS announces second quarter fiscal 2008 financial results 3ARIUS announces second quarter fiscal 2008 financial results 4ARIUS announces second quarter fiscal 2008 financial results 5ARIUS announces second quarter fiscal 2008 financial results 6ARIUS announces second quarter fiscal 2008 financial results 7ARIUS announces second quarter fiscal 2008 financial results 8ARIUS announces second quarter fiscal 2008 financial results 9ARIUS announces second quarter fiscal 2008 financial results 10ARIUS announces second quarter fiscal 2008 financial results 11ARIUS announces second quarter fiscal 2008 financial results 12ARIUS announces second quarter fiscal 2008 financial results 13ARIUS announces second quarter fiscal 2008 financial results 14ARIUS announces second quarter fiscal 2008 financial results 15
(Date:11/24/2009)...9) -- The Wildlife Conservation Society (WCS) anno...ning population of Siberian tigers has likely decl...ing and habitat loss. , WCS says the... needs to be done to protect remaining populations...report was released by the Siberian Tiger Monitori...
(Date:11/23/2009)...dence that the "synergistic" effect of early-life ... and indoor endotoxin causes more harm to developi..., Environmental health scientists at the Universi...wn that children exposed to both high levels of tr...g early life are six times more likely to experien...
(Date:11/23/2009)...ts gathered this week for the seventh annual Natio...This year,s topic, "Synthetic Biology," brought to...ers to explore the engineering, scientific, and so...hetic biology. , Bonnie L. Bassler, professor of...s year,s conference chair, challenged the attendee...
Breaking Biology News(10 mins):Report shows dramatic decline in Siberian tigers 2Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Synthetic biology offers new opportunities for interdisciplinary collaboration 2MTVs Season Finale of 16 26 Pregnant Hit Series Highs Among Both P12 34 281 9 29 and Total Viewers 282 1 Million 29 Thursday Ranking as the Number 52155 1MTVs Season Finale of 16 26 Pregnant Hit Series Highs Among Both P12 34 281 9 29 and Total Viewers 282 1 Million 29 Thursday Ranking as the Number 52155 2MTVs Season Finale of 16 26 Pregnant Hit Series Highs Among Both P12 34 281 9 29 and Total Viewers 282 1 Million 29 Thursday Ranking as the Number 52155 3MTVs Season Finale of 16 26 Pregnant Hit Series Highs Among Both P12 34 281 9 29 and Total Viewers 282 1 Million 29 Thursday Ranking as the Number 52155 4MTVs Season Finale of 16 26 Pregnant Hit Series Highs Among Both P12 34 281 9 29 and Total Viewers 282 1 Million 29 Thursday Ranking as the Number 52155 5OncoGenex Pharmaceuticals to Raise 249 5 Million Through Sale of Common Stock 13100 1OncoGenex Pharmaceuticals to Raise 249 5 Million Through Sale of Common Stock 13100 2OncoGenex Pharmaceuticals to Raise 249 5 Million Through Sale of Common Stock 13100 3TorreyPines Receives Notice of Delisting from Nasdaq Global Market 13095 1TorreyPines Receives Notice of Delisting from Nasdaq Global Market 13095 2
... Whether or not a fertilized mammalian egg ultimat...y the winner of a tug of war between two different...nt pathways they control, according to a new study...ists. , In their experiments in mice, the research...are in equal balance in the early stages of develo...
... A gene that is associated with osteoarthritis and...be responsible for preventing the onset of osteoar... led by Rhode Island Hospital. The matrilin-3 gene...bone mineral density in adulthood and prevents ost...in-3 have previously been linked to certain skelet...
... Most women at high risk for breast cancer do not ...tamoxifen, according to a new analysis by research...rgh and McMaster University in Ontario, Canada. In...s an extraordinarily expensive cancer-prevention s...of life saved. The study will be published in the ...
Other Biology News:Genetic tug of war determines sexual differentiation 2Genetic tug of war determines sexual differentiation 3Matrilin-3 gene discovered to prevent onset of osteoarthritis 2Matrilin-3 gene discovered to prevent onset of osteoarthritis 3Tamoxifen for breast cancer prevention does not benefit most women 2Tamoxifen for breast cancer prevention does not benefit most women 3
Normal Chicken Serum from Equitech-Bio
Pig Serum Non-Sterile Trace-Hemolyzed from Pel-Freez Biologicals
Mouse Anti-Keap1 Monoclonal Antibody, Unconjugated, Clone 333116 from R&D Systems
Normal Guinea Pig Serum from Equitech-Bio
Biology Products: